We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
Read MoreHide Full Article
Shares of Karyopharm Therapeutics Inc. ((KPTI - Free Report) ) rallied 36% after the FDA granted accelerated approval to oral Xpovio (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM), who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.Selinexor is the first FDA-approved medication for this indication. Shares of the company have increased 111% year to date compared with the industry’s growth of 11.8%.
The approval was supported by data from the phase IIb STORM study in patients with RRMM. In the study,122 patients were treated with selinexor 80 mg in combination with dexamethasone 20 mg on days 1 and 3 of every week. A pre-specified subgroup analysis of 83 patients, whose disease was refractory to prior treatments, showed that the benefit-risk ratio was greater in the more heavily pretreated population than the overall trial population. The overall response rate, which served as the basis for Xpovio’s accelerated approval, was 25.3% in this subgroup. The subgroup included 1 stringent complete response, no complete responses, 4 very good partial responses and 16 partial responses. The median time to first response for these patients was 4 weeks and the median duration of response was 3.8 months, per the data.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory study. The ongoing, randomized phase III BOSTON trial evaluating Xpovio in combination with Velcade (bortezomib) and low-dose dexamethasone will serve as the confirmatory study.
Karyopharm expects Xpovio to become commercially available in the United States on or before Jul 10, 2019. A Marketing Authorization Application for the drug is also currently under review by the European Medicines Agency.
We remind investors that last month, Johnson & Johnson (JNJ - Free Report) announced that its subsidiary Janssen received approval from the FDA for label expansion of its blockbuster drug, Darzalex, to treat newly diagnosed multiple myeloma (“MM”) patients, who are ineligible for autologous stem cell transplant (“ASCT”). The approval is for Darzalex in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone (Rd). The drug is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma, such as frontline and relapsed settings.
These include combination studies with other cancer drugs like Roche Holding AG’s (RHHBY - Free Report) Tecentriq, Bristol-Myers’ Opdivo and Amgen’s Kyprolis.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
Shares of Karyopharm Therapeutics Inc. ((KPTI - Free Report) ) rallied 36% after the FDA granted accelerated approval to oral Xpovio (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM), who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.Selinexor is the first FDA-approved medication for this indication. Shares of the company have increased 111% year to date compared with the industry’s growth of 11.8%.
The approval was supported by data from the phase IIb STORM study in patients with RRMM. In the study,122 patients were treated with selinexor 80 mg in combination with dexamethasone 20 mg on days 1 and 3 of every week. A pre-specified subgroup analysis of 83 patients, whose disease was refractory to prior treatments, showed that the benefit-risk ratio was greater in the more heavily pretreated population than the overall trial population. The overall response rate, which served as the basis for Xpovio’s accelerated approval, was 25.3% in this subgroup. The subgroup included 1 stringent complete response, no complete responses, 4 very good partial responses and 16 partial responses. The median time to first response for these patients was 4 weeks and the median duration of response was 3.8 months, per the data.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory study. The ongoing, randomized phase III BOSTON trial evaluating Xpovio in combination with Velcade (bortezomib) and low-dose dexamethasone will serve as the confirmatory study.
Karyopharm expects Xpovio to become commercially available in the United States on or before Jul 10, 2019. A Marketing Authorization Application for the drug is also currently under review by the European Medicines Agency.
We remind investors that last month, Johnson & Johnson (JNJ - Free Report) announced that its subsidiary Janssen received approval from the FDA for label expansion of its blockbuster drug, Darzalex, to treat newly diagnosed multiple myeloma (“MM”) patients, who are ineligible for autologous stem cell transplant (“ASCT”). The approval is for Darzalex in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone (Rd). The drug is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma, such as frontline and relapsed settings.
These include combination studies with other cancer drugs like Roche Holding AG’s (RHHBY - Free Report) Tecentriq, Bristol-Myers’ Opdivo and Amgen’s Kyprolis.
Karyopharm Therapeutics Inc. Price
Karyopharm Therapeutics Inc. price | Karyopharm Therapeutics Inc. Quote
Zacks Rank
Karyopharm currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%. This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>